These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23938176)

  • 1. Pharmacological approaches to treating negative symptoms: a review of clinical trials.
    Arango C; Garibaldi G; Marder SR
    Schizophr Res; 2013 Nov; 150(2-3):346-52. PubMed ID: 23938176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunct mirtazapine for negative symptoms of schizophrenia.
    Phan SV; Kreys TJ
    Pharmacotherapy; 2011 Oct; 31(10):1017-30. PubMed ID: 21950644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of negative symptoms in schizophrenia.
    Möller HJ; Czobor P
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):567-78. PubMed ID: 25895634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopharmacology of the negative symptoms: current status and prospects for progress.
    Davis MC; Horan WP; Marder SR
    Eur Neuropsychopharmacol; 2014 May; 24(5):788-99. PubMed ID: 24252823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of antidepressants in the treatment of negative symptoms of schizophrenia].
    Palomba A; Lodovighi MA; Belzeaux R; Adida M; Azorin JM
    Encephale; 2015 Dec; 41(6 Suppl 1):6S36-40. PubMed ID: 26776391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do negative symptoms respond to pharmacological treatment?
    Kane JM; Mayerhoff D
    Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
    [No Abstract]   [Full Text] [Related]  

  • 7. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should patients with schizophrenia receive antidepressants?
    Terevnikov V; Stenberg JH; Joffe G
    Duodecim; 2017; 133(5):465-71. PubMed ID: 29205993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological approaches to the management of schizophrenia: 10 years on.
    Castle D; Keks N; Newton R; Schweitzer I; Copolov D; Paoletti N; Burrows G; Tiller J
    Australas Psychiatry; 2013 Aug; 21(4):329-34. PubMed ID: 23616381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials.
    Levine SZ; Leucht S
    Schizophr Res; 2014 Jun; 156(1):107-14. PubMed ID: 24794879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Negative symptoms in schizophrenia: new pharmacological approaches].
    Lodovighi MA; Palomba A; Belzeaux R; Adida M; Azorin JM
    Encephale; 2015 Dec; 41(6 Suppl 1):6S41-9. PubMed ID: 26776392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing Negative Symptoms of Schizophrenia: How Far Have We Come?
    Kantrowitz JT
    CNS Drugs; 2017 May; 31(5):373-388. PubMed ID: 28397113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac?
    Buckley PF; Stahl SM
    Acta Psychiatr Scand; 2007 Feb; 115(2):93-100. PubMed ID: 17244172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.
    Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Apr; 255(2):83-93. PubMed ID: 15812601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
    Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
    Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia.
    Levine SZ; Leucht S
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):812-7. PubMed ID: 22507686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.